PMID- 29517678
OWN - NLM
STAT- MEDLINE
DCOM- 20180319
LR  - 20211204
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 10
DP  - 2018 Mar
TI  - The clinical significance of COL5A2 in patients with bladder cancer: A 
      retrospective analysis of bladder cancer gene expression data.
PG  - e0091
LID - 10.1097/MD.0000000000010091 [doi]
LID - e0091
AB  - The present study was aimed to investigate the relationship between the 
      expression of collagen type V alpha 2 chain (COL5A2) and clinical outcomes of 
      patients with bladder cancer.Chi-square test and log-rank-based survival analysis 
      were performed to assess the correlation of COL5A2 expression with clinical 
      characteristics and survivals of patients with bladder cancer using GSE13507. 
      Gene set enrichment analysis was conducted to study the relevant 
      mechanisms.Bladder cancer patients in COL5A2 low expression group were associated 
      with better invasiveness (P < .0001), tumor grade (P = .001), T staging 
      (P < .0001), N staging (P = .002), cancer specific survival (P < .0001), overall 
      survival (P < .0001), and a trend of better M staging (P = .053) than those in 
      COL5A2 high expression group.COL5A2 might affect the progression of bladder 
      cancer through "Coagulation," "Hypoxia," "Apical junction," "Ultraviolet 
      response," "Epithelial mesenchymal transition," "Angiogenesis," "KRAS (KRAS 
      proto-oncogene, GTPase) signaling,""Complement,""IL2-STAT5-signaling," 
      "Inflammatory response," "IL6-JAK-STAT3-signaling," "Myogenesis," "TNF alpha 
      signaling," "Apoptosis," and "Hedgehog-signaling."Our results demonstrated that 
      COL5A2 was correlated with poor clinical outcomes and survivals of patients with 
      bladder cancer, suggesting that it could be regarded as a biomarker of bladder 
      cancer.
FAU - Zeng, Xian-Tao
AU  - Zeng XT
AD  - Department of Urology Center for Evidence-Based and Translational Medicine, 
      Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
FAU - Liu, Xiao-Ping
AU  - Liu XP
FAU - Liu, Tong-Zu
AU  - Liu TZ
FAU - Wang, Xing-Huan
AU  - Wang XH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Collagen Type V)
RN  - 0 (MAS1 protein, human)
RN  - 0 (Proto-Oncogene Mas)
SB  - IM
MH  - Aged
MH  - Biomarkers, Tumor/genetics
MH  - Collagen Type V/*analysis
MH  - Disease Progression
MH  - Female
MH  - *Gene Expression
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Invasiveness/genetics
MH  - Neoplasm Staging
MH  - Proto-Oncogene Mas
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Urinary Bladder/pathology
MH  - Urinary Bladder Neoplasms/*genetics/mortality/pathology
PMC - PMC5882427
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2018/03/09 06:00
MHDA- 2018/03/20 06:00
PMCR- 2018/03/09
CRDT- 2018/03/09 06:00
PHST- 2018/03/09 06:00 [entrez]
PHST- 2018/03/09 06:00 [pubmed]
PHST- 2018/03/20 06:00 [medline]
PHST- 2018/03/09 00:00 [pmc-release]
AID - 00005792-201803090-00023 [pii]
AID - MD-D-17-07212 [pii]
AID - 10.1097/MD.0000000000010091 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Mar;97(10):e0091. doi: 10.1097/MD.0000000000010091.